Clinical trials · New York
Renal Cell Carcinoma clinical trials in New York
We’re tracking 85 recruiting renal cell carcinoma studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07227870RecruitingPhase 2
Study of L19IL2/TNF for advanced basal cell carcinoma
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
New York, New YorkAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
New York, New YorkAges 18 years+ - NCT06222593RecruitingPhase 1/Phase 2
Bicalutamide plus sunitinib for TKI-resistant kidney cancer
This trial tests a combination of two drugs—bicalutamide and sunitinib—for people with advanced kidney cancer that no longer responds to TKI therapy. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Buffalo, New YorkAges 18 years+ - NCT05256225RecruitingPhase 3
Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Albany, New YorkAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
New York, New YorkAges 18 years+ - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
The Bronx, New YorkAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Elmhurst, New YorkAges 40–75 - NCT05419089RecruitingPhase 2
Testing robotic surgery for HPV-related throat cancer patients
This Phase 2 trial studies a robotic surgery approach for certain HPV-related throat cancers, using HPV blood tests before and after surgery to guide care. If your cancer is HPV-related and your HPV blood test results match the trial targets, you may be able to join and help improve treatment for future patients.
New York, New YorkAges 18 years+ - NCT03067181RecruitingPhase 3
Active surveillance and chemotherapy for germ cell tumors
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
Albany, New YorkAges Any age - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT03215719RecruitingPhase 2
De-escalating treatment for HPV-positive throat cancer with low-risk signals
This Phase 2 trial tests whether people with HPV-positive oropharyngeal (throat) cancer who look “lower risk” can safely receive less intensive treatment. It uses HPV blood test results and cancer staging scans to guide whether treatment can be de-escalated.
New York, New YorkAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Brooklyn, New YorkAges 18 years+ - NCT05583708RecruitingPhase 2
Trial tests targeted radiation plus immunotherapy after anti–PD-1 failure
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
New York, New YorkAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
East Syracuse, New YorkAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Brooklyn, New YorkAges 18 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT05799274RecruitingPhase 1
Safety study of a new PET imaging drug for cancers
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
The Bronx, New YorkAges 18 years+ - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
New York, New YorkAges 18 years+ - NCT05307939RecruitingPhase 2
Using tumor DNA tests to time treatment for HPV throat cancer
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
East White Plains, New YorkAges 18 years+ - NCT05544136RecruitingPhase 2
Study of lower radiation and chemo for head and neck cancer
This study tests whether giving lower doses of radiation and chemotherapy is safe and effective for people with certain head and neck cancers. It aims to reduce side effects while keeping the treatment successful.
Commack, New YorkAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
New York, New YorkAges 18 years+ - NCT04402788RecruitingPhase 2/Phase 3
Radiation added to immune therapy for extensive small cell lung cancer
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
Camillus, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Buffalo, New YorkAges 18 years+
Renal Cell Carcinoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting renal cell carcinoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 14 studies
- Montefiore Medical Center · 7 studies
- NYU Langone Health · 7 studies
- Memorial Sloan Kettering Commack · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Mount Sinai Health System · 4 studies
- Mount Sinai Hospital · 4 studies
- NYU Langone Hospital - Long Island · 4 studies
What taking part in a renal cell carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Renal Cell Carcinoma trials in other states
Common questions
- Are there renal cell carcinoma clinical trials in New York?
- Yes. We're currently tracking 85 recruiting renal cell carcinoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a renal cell carcinoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New renal cell carcinoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.